Clinical Trial Update: Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for an AAV gene therapy targeting CNGA3 achromatopsia (A Clarity Clinical Trial) across Phase 1 and Phase 2; status is active_not_recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achromatopsia

Drugs mentioned

• AAV gene therapy targeting CNGA3 (AAV CNGA3 gene therapy)

Snippet

Sponsor: Beacon Therapeutics | Conditions: Achromatopsia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING